In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, and Matthew Binnicker, Ph.D., a microbiologist and virologist and chief scientific officer of Mayo Clinic Laboratories, discuss recent developments in viral infections.

In this episode of the “Leveraging the Laboratory” podcast, host Jane Hermansen, outreach manager at Mayo Clinic Laboratories, is joined by Travis Engelhaupt, digital experience director, and Naomi Lovell, project manager. Together, they discuss website trends and best practices.

Register now – Nov. 19, 2025: Regulatory compliance and recent policy changes at the federal and state levels relevant to hospital laboratory outreach programs.

Discussion is an effective pedagogical strategy to facilitate a learning experience and assess understanding. Carrie Bowler, Program Manager of Staff Development in the Department of Laboratory Medicine and Pathology, discusses the benefits of discussion as a strategy.

After a long wait, the U.S. Food and Drug Administration has finally approved the Elecsys Troponin T Gen 5 STAT blood test. Recently, the Beckman hscTnI assay was also approved. These high-sensitivity troponin assays will benefit emergency departments across the country because the results will allow for earlier and faster recognition of acute myocardial infarction, which interrupts the blood supply to an area of the heart.

How Your Genes Determine which Medications Work Best for You The drugs available today to treat diseases are powerful agents that work as intended for[...]

This “Phlebotomy” webinar will discuss how a patient’s “experience” is the entirety of all the interactions that person has had within the health care system. Each member of a health care team plays a role in enhancing patient satisfaction, which contributes to the patient experience.

Mayo Medical Laboratories, the global reference laboratory of Mayo Clinic, has changed its name to Mayo Clinic Laboratories.

Reilly Hannon, a student in the Mayo Clinic Medical Laboratory Science program, reflects on her course in hemostasis.

Effective November 9, 2018, our business name will change from Mayo Collaborative Services, LLC, doing business as (d/b/a) Mayo Medical Laboratories to Mayo Collaborative Services, LLC, d/b/a Mayo Clinic Laboratories. The change to Mayo Clinic Laboratories will more accurately reflect the benefit we are able to bring to our clients every day.

Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.

Chromium and cobalt blood tests are used to monitor exposure to these elements. Both of these elements are naturally occurring and widely distributed in the environment. Previously, serum samples were collected and used to monitor patients with metal-on-metal implants, but serum can easily be contaminated during the harvesting and separation of the serum from the cellular blood components causing incorrect results. By using the new EDTA anticoagulated whole-blood test, which is collected in a trace element tube instead of using serum, the risk of contamination is significantly reduced.

Gadolinium-based contrast agents (GBCAs) have revolutionized MRIs by increasing the clinical utility and detection sensitivity of these exams. GBCAs also contain gadolinium, a rare earth metal with unique chemical properties. This article discusses the recent discovery that small amounts of gadolinium remain in human brain tissue following intravenous administration of GBCAs.

In this month’s “Hot Topic,” Brad Karon, M.D., Ph.D., describes how pseudohyperkalemia has many causes, from collection techniques, processing, and even transport. This presentation focuses on the various preanalytic and analytic causes of pseudohyperkalemia and what you as a phlebotomist can do to prevent it.

Many patients may have flare-ups of their disease, or they may stop responding to treatment. In these situations, the clinician may choose to increase the dose administered or recommend more frequent injections. One cause of decreased response to treatment is the appearance of anti-drug antibodies or “immunogenicity.”